Efficacy and safety of envafolimab in the treatment of advanced dMMR/MSI‑H solid tumors: A single‑arm meta‑analysis

In November 2021, the National Medical Products Administration (China) approved the marketing of envafolimab injection for the treatment of advanced defective mismatch repair (dMMR)/high microsatellite instability (MSI-H) solid tumors. Envafolimab became the first domestic PD-L1 inhibitor approved i...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Shaoqing, Gai, Chunyue, Li, Baokun, Wang, Guiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398626/
https://www.ncbi.nlm.nih.gov/pubmed/37545619
http://dx.doi.org/10.3892/ol.2023.13937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398626/
https://www.ncbi.nlm.nih.gov/pubmed/37545619
http://dx.doi.org/10.3892/ol.2023.13937

Ejemplares similares